An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

Completed · Phase 3

Conditions studied: Carcinoma, Non-Small-Cell Lung

In brief

This is a Phase 3 trial comparing the safety and anti-tumor activity of PF-02341066 versus pemetrexed or docetaxel in patients with advanced non-small cell lung cancer with specific gene profile involving the ALK gene after failure of one previous chemotherapy regimen that included one platinum drug.

Key facts

Study ID

NCT00932893

Run by

Pfizer

People needed

347

Starts

2009-09-01

Expected to finish

2016-01-01

Last updated by the study team

2017-01-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• histologically or cytologically proven diagnosis of non-small cell lung cancer
• positive for the ALK fusion gene (test provided by a central laboratory)
• must have had disease progression after only one prior chemotherapy and that regimen but must have included one platinum drug
• tumors must be measurable

You may not qualify if…

• prior treatment with PF-02341066
• current treatment in another clinical trial

Where it is running

• Comprehensive Blood and Cancer Center — Bakersfield, California, United States
• Tower Cancer Research Foundation — Beverly Hills, California, United States
• Tower Hematology Oncology Medical Group — Beverly Hills, California, United States
• UCSD Medical Center -La Jolla — La Jolla, California, United States
• Moores UC San Diego Cancer Center — La Jolla, California, United States
• Drug Shipping Address: [IRB# 10-001530] Ronald Reagan UCLA — Los Angeles, California, United States
• Ronald Reagan UCLA Medical Center — Los Angeles, California, United States
• UCLA Hematology Oncology — Los Angeles, California, United States
• UCLA Ophthalmic Oncology Center — Los Angeles, California, United States
• University of California-Los Angeles — Los Angeles, California, United States
• Ship Drug To : Kevin Kong- University of California, Irvine-Pharmacy — Orange, California, United States
• University of California, Irvine-Medical Center — Orange, California, United States
• Stanford University-Cancer Center — Palo Alto, California, United States
• UC Davis Cancer Center — Sacramento, California, United States
• University of California Davis Medical Center — Sacramento, California, United States
• UCSD Medical Center- Hillcrest — San Diego, California, United States
• Santa Monica-UCLA Medical Center and Orthopaedic Hospital — Santa Monica, California, United States
• University of California, Los Angeles — Santa Monica, California, United States
• Redwood Regional Medical Group, Inc. — Santa Rosa, California, United States
• Drug Shipment: University of Colorado Cancer Center, Anschutz Cancer Pavilion — Aurora, Colorado, United States
• University of Colorado Denver (CTRC) — Aurora, Colorado, United States
• Unviersity of Colorado Hospital, Anschutz Cancer Pavilion — Aurora, Colorado, United States
• Unviersity of Colorado Hospital, Anschutz Inpatient Pavilion — Aurora, Colorado, United States
• Kaiser Permanente — Denver, Colorado, United States
• University of Arkansas for Medical Research, Winthrop Rockefeller Cancer Institute — Little Rock, Arkansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.